AIM Biotech
  • HOME
    • ABOUT US
    • CAREERS
    • NEWSROOM
  • TECHNOLOGY
    • TECHNOLOGY
    • APPLICATIONS
    • PUBLICATIONS
  • PRODUCTS
    • CHIPS
    • ACCESSORIES
    • RESEARCH SERVICES
  • PROTOCOLS
    • GENERAL PROTOCOLS
    • APPLICATION-SPECIFIC PROTOCOLS
    • VIDEOS
    • PROTOCOL SUBMISSION
  • SUPPORT
    • CONTACT US
    • FAQ
    • TIPS & TRICKS
    • BROCHURES
    • APPLICATION NOTES
    • FORUMS
  • STORE
    • DISTRIBUTORS

Cell paper on "Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma" features AIM Biotech chips for Ex Vivo Immune Checkpoint Assays to Validate Key Discoveries

1/11/2018

0 Comments

 
Picture
Picture
Sade-Feldman et al from the Massachusetts General Hospital Cancer Center, the Broad Institute, the Dana Farber Cancer Institute and others demonstrated in the Cell paper that: 
  • Single-cell RNA-seq reveals distinct CD45 + cells associated with clinical outcome 
  • The balance between two CD8 + T cell states is linked with tumor regression 
  • TCF7 +CD8 + T cell frequency in tumor tissue predicts response and better survival 
  • Dual blockade of CD39 with different checkpoint proteins enhances immunity
​Ex vivo culture of murine-derived organotypic tumor spheroids (MDOTS) in AIM Biotech chips is able to recapitulate the immune checkpoint response.  These assays were used to validate the authors' discoveries by co-culturing the MDOTS with defined CD8+ T cell populations (CD39+/TIM3+, CD39-/TIM3- or mixed 1:1) (see figure 5D).
0 Comments

    Archives

    January 2020
    December 2019
    November 2018
    October 2018
    August 2018
    July 2018
    April 2018
    November 2017
    July 2017
    April 2017
    December 2016
    July 2016
    March 2016
    January 2016
    December 2015
    September 2015
    August 2015

    Categories

    All

    RSS Feed

Picture
About AIM Biotech
Contact Us
Newsroom
Subscribe to AIM Biotech's mailing list

This website and its content is copyright of AIM Biotech Pte. Ltd.
​© AIM Biotech Pte. Ltd. 2020. All rights reserved.